Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20621409 | 1.00 | CYP1A2 (0.41) | CYP1A2LMNAGABRA1SLC6A2HTR2C | |
| SCHEMBL19779815 | 0.83 | TSHR (0.43) | CYP1A2LMNASLC6A2HTR2CHTR2B | |
| SCHEMBL19880550 | 0.81 | SMN1; SMN2 (0.34) | CYP1A2LMNASLC6A2HTR2CHTR2B | |
| SCHEMBL533867 | 0.80 | SMN1; SMN2 (0.55) | CYP1A2LMNASLC6A2HTR2CHTR2B | |
| SCHEMBL2010954 | 0.80 | SMN1; SMN2 (0.55) | CYP1A2LMNASLC6A2HTR2CHTR2B | |
| SCHEMBL533868 | 0.80 | SMN1; SMN2 (0.55) | CYP1A2LMNASLC6A2HTR2CHTR2B | |
| SCHEMBL19768996 | 0.79 | CYP1A2 (0.37) | CYP1A2LMNAGABRA1SLC6A2HTR2C | |
| SCHEMBL19779674 | 0.79 | CYP1A2 (0.37) | CYP1A2LMNAGABRA1SLC6A2HTR2C | |
| SCHEMBL19768992 | 0.79 | GABRA1 (0.41) | CYP1A2LMNAGABRA1SLC6A2HTR2C | |
| SCHEMBL19779453 | 0.79 | GABRA1 (0.41) | CYP1A2LMNAGABRA1SLC6A2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9896432-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | CYP1A2 4769/4885LMNA 3475/4885GABRA1 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.